Navigation Links
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
Date:3/3/2009

he total duration of antibiotic therapy for each patient should be 5 to 14 days. The results of this study are expected in early 2010.

This second Phase II trial in cIAIs, follows a Phase II clinical trial of NXL104/cetazidime in hospitalized patients with complicated urinary tracts infections (cUTIs). This study which began in November is due to complete in late 2009.

In completed Phase I studies in healthy subjects NXL104/ceftazidime was generally well tolerated and the pharmacokinetics of the two components were well matched. Additional studies in special populations are ongoing.

Iain Buchanan, Novexel's CEO, said, "The start of this second Phase II study demonstrates Novexel's commitment to developing NXL104 in combination with ceftazidime in a broad range of indications where resistant Gram negative bacteria are present or are suspected. NXL104 has the ability to inhibit the activity of a broader range of clinically important beta-lactamases than currently marketed beta-lactam inhibitors and we believe that this combination product could provide an important new treatment option in the hospital."

Under an independent development program, Forest Laboratories (NYSE : FRX) will combine NXL104 in a treatment regimen with Forest's ceftaroline, a novel, bactericidal injectable broad spectrum cephalosporin. Ceftaroline is being developed as a therapeutic agent for the treatment of gram-positive pathogens including methicillin resistant staphylococcus aureus (MRSA), and multi-drug resistant streptococcus pneumoniae (MDRSP), as well as common gram-negative organisms. Ceftaroline is being studied as a monotherapy in Phase III clinical trials by Forest. In January 2008, Novexel granted Forest a license to develop, manufacture and commercialise NXL104, only in combination with ceftaroline, in North America.

Novexel retains worldwide rights on the NXL104/ceftazidime combination.


'/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
4. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
5. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
6. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
7. Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Nov. 28, 2014  Valeant Pharmaceuticals International, Inc. ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals ... of its outstanding 6.875% Senior Notes due 2018, ... on December 29, 2014 and has mailed an ... the redemption, approximately US$500 million aggregate principal amount ...
(Date:11/28/2014)... , Nov. 28, 2014 /CNW Telbec/ - Ergoresearch Ltd ... appointment of Mrs. Dominique Boudreau who will ... team. Mrs. Dominique Boudreau was acting as ... occupied similar duties for more than seven years for ... in January 2013.  Mrs. Boudreau replaces Mr. Greco who ...
(Date:11/28/2014)... Aratana Therapeutics, Inc. (NASDAQ: PETX ), ... acquisition, development and commercialization of innovative biopharmaceutical products for ... it will present at the 26 th Annual ... 2014, at the New York Palace Hotel in ... St. Peter , M.D., President and Chief Executive Officer, ...
Breaking Medicine Technology:Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 2Ergoresearch announces the appointment of its new Vice Président Finance 2Ergoresearch announces the appointment of its new Vice Président Finance 3Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2
... Measuring the body temperatures of newborns with temporal artery ... by axillary (under arm) thermometry, the clinically recommended method ... to a new study reported in Advances in ... first published clinical analysis evaluating the accuracy of temporal ...
... 18, 2011 BB&T Capital Markets served as the ... Comfort, the leading developer, manufacturer and marketer of therapeutic ... sale to DJO Global, an international provider of medical ... management based in Vista, Calif. Dr. Comfort generated net ...
Cached Medicine Technology:Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 2Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns 3BB&T Advises Dr. Comfort on Its Sale to DJO Global in Transaction Valued at $254.6 Million 2
(Date:11/28/2014)... The report “Poxvirus Infections Pipeline Review ... development for Poxvirus Infections, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Poxvirus Infections and special features on late-stage and ...
(Date:11/28/2014)... Recently, SWAccessControl.com, a renowned smartware manufacturer, has announced ... these high end products are offered at discounted rates, ... last from today to Dec 16, 2014. , The ... the promotion. We are proud of our new access ... information about our hottest items, we have listed some ...
(Date:11/28/2014)... York, NY (PRWEB) November 28, 2014 ... physical therapy techniques such as Dynamic Neuromuscular Stabilization, ... and gait/motion analysis. After moving to upgraded facilities ... and running clinic. Now, owner Dr. Lev Kalika ... performance and injury prevention lab in the country. ...
(Date:11/28/2014)... 28, 2014 (HealthDay News) -- People with diabetes face a ... help keep you healthy, an expert says. "With the ... deal with the events, the family you,ll be visiting and ... Association of Diabetes Educators, said in an association news release. ... be healthy." One idea is to make a healthy ...
(Date:11/28/2014)... Sunnyvale, CA (PRWEB) November 28, 2014 ... on December 2, 2014. This national movement was ... their communities by giving to local charities and causes. ... Thanksgiving Holiday, coincides with the kickoff of the holiday ... Friday is to shopping and Cyber Monday is to ...
Breaking Medicine News(10 mins):Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 2Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 3Health News:Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014 4Health News:New Access Control Systems Now Offered At Low Prices By Smartware Manufacturer SWAccessControl.com 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Holiday Eating Tips for People With Diabetes 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 3
... Group, Inc. (SSI),announced today that Siemens Healthcare has ... through SSI,s ClickON(R), ClickON(R),s LinX,offering, and content partnership., ... Healthcare customers,to take advantage of a wide range ... Status, Secondary Billing, Audit Tracking and Note,Posting for ...
... had to become a "difficult patient" before she could get ... her health. , And once the diagnosis was made, she ... "difficult" before she could get the best treatment for scleroderma, ... is a major element. , Mayer, a research assistant professor ...
... PALM BEACH, Fla., Sept 10 If a ... bag of chips or a quart of ice ... emotional eating, which can,now be helped with The ... ), the first vegan, gluten-free vitamin with human,clinical ...
... is a unique online community for people who support affordable health ... ... Columbus, OH (PRWEB) September 10, 2008 -- While politicians dispense their ... are invited to do the same online. The common place to ...
... launches a unique, national weight and stress management program based upon ... ... (PRWEB) September 10, 2008 -- With high gasoline prices, depressed real ... Americans are skyrocketing. For those that attempt to eat their stress ...
... personalized service educates clients about Medicare; identifies best options and ... ... Belleville, Ill. (Vocus) September 10, 2008 ... the services it offers to individuals with disabilities with the ...
Cached Medicine News:Health News:SSI Announces Agreement with Siemens Healthcare 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 2Health News:Survival instincts propel 'difficult patient' to insist on quality care 3Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 2Health News:Stress-Related and Emotional Eating Can Be Curbed With the Vitamin Code(TM) Perfect Weight Formula 3Health News:Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue 2Health News:Are You A Stress Eater? Revolutionary Program Reduces Overall Stress and Stress Eating Tendencies 2Health News:Are You A Stress Eater? Revolutionary Program Reduces Overall Stress and Stress Eating Tendencies 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 2Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 3Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 4Health News:Allsup's New Medicare Advisor Program Helps People with Disabilities Make Sound Healthcare Coverage Decisions 5
... , ... event is to use an ... environment. But will the device be durable enough? Can you depend, ... its signal quality? Will the battery last? Is it comfortable, ...
... new features and state-of-the ... innovation, the SuperStim brain ... stimulation up to 30 ... and transcranial stimulation up ...
... high-volume analyzer that builds upon the field-proven ... and the latest Olympus technological advances. The ... with up to 147 on-board chemistries and ... Choose from Olympus 122 test menu, including ...
... The AU640 e is ... mid-sized to large laboratories and hospitals. ... the AU640es field-proven reliability and Olympus ... chemistries, urine chemistry, specific proteins, esoteric ...
Medicine Products: